JAZZ
Jazz Pharmaceuticals plc · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -2.5% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 137 | +4 | 47.51M | $11.43B | +7 | −2 |
| Q1 2026 | 135 | -10 | 49.63M | $8.67B | +4 | −14 |
| Q4 2025 | 144 | +2 | 48.56M | $7.62B | +2 | — |
| Q3 2025 | 20 | 0 | 25.68M | $3.38B | +1 | −1 |
| Q2 2025 | 17 | -1 | 21.49M | $2.28B | +1 | −2 |
| Q1 2025 | 15 | 0 | 8.34M | $1.04B | +1 | −1 |
| Q4 2024 | 15 | 0 | 8.56M | $1.05B | +1 | −1 |
| Q3 2024 | 14 | -2 | 7.38M | $822.21M | — | −2 |
| Q2 2024 | 16 | — | 7.74M | $826.28M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 1.97M | -0.1% | $244.15M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 2 | Capital World Investors ✦ | 1.93M | +0.2% | $239.34M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.15M | +5.6% | $143.43M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Renaissance Technologies ✦ | 1.04M | +4.3% | $129.68M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 696.94K | +37.6% | $86.53M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 490.31K | -8.1% | $59.82M | 0.1% | ▼ Trim | 4 | SEC ↗ ×4 |
| 7 | Two Sigma Investments ✦ | 344.41K | +84.0% | $42.76M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | Bridgewater Associates ✦ | 250.95K | +30.7% | $31.16M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 9 | Point72 Asset Management ✦ | 173.87K | +106.6% | $21.59M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 100.96K | +141.5% | $12.53M | 0.0% | ▲ Add | 4 | SEC ↗ ×6 |
| 11 | D. E. Shaw & Co. ✦ | 66.19K | -78.1% | $8.22M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 12 | Gotham Asset Management ✦ | 50.40K | +233.9% | $6.26M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 42.44K | +11.1% | $5.27M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Millennium Management ✦ | 21.45K | -96.5% | $2.66M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 15 | Adage Capital Partners ✦ | 13.00K | New | $1.61M | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $1.61M | 0.0% |
Exited
| Marshall Wace | $7.31M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 568 holders, 63.82M shares, $11.28B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 2.00K sh · $472,800
Director · 6.00K sh · $1.38M
Officer · 1.20K sh · $289,128
Officer · 2.00K sh · $486,060
Director · 6.00K sh · $1.50M
Officer · 300 sh · $75,828
Officer · 18.11K sh · $4.53M
Officer · 9.26K sh · $2.33M
Officer · 11.42K sh · $2.84M
Officer · 18.19K sh · $4.51M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology